Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate

Medical Decision Making

Volumn 26, Issue 2, 2006, Pages 194-206

  Mobley, Lee R ^a   Hoerger, Thomas J ^a   Wittenborn, John S ^a   Galuska, Deborah A ^b   Rao, Jaya K ^b  

^a RTI INTERNATIONAL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Alendronate; Hormone replacement therapy; Osteoporosis; Raloxifene

Indexed keywords

ALENDRONIC ACID; RALOXIFENE;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; OSTEOPOROSIS; OUTCOMES RESEARCH; QUALITY ADJUSTED LIFE YEAR; SCREENING; SENSITIVITY ANALYSIS; SUBSTITUTION THERAPY;

AGED; ALENDRONATE; COST-BENEFIT ANALYSIS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MARKOV CHAINS; MASS SCREENING; OSTEOPOROSIS; QUALITY-ADJUSTED LIFE YEARS; RALOXIFENE; UNITED STATES;

EID: 33646716215     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X06286478     Document Type: Article

References (46)

1. Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24-35.
2. Cummings SR, Black DM, Nevitt NC, et al. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA. 1990;263:665-8.
3. Agency for Healthcare Research and Quality. Screening for Postmenopausal Osteoporosis. Systematic Evidence Review No. 17. Rockville, MD: Agency for Healthcare Research and Quality; 2002.
4. US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137:526-8.
5. Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Report of a World Health Organization (WHO) Study Group. Technical Report Series No. 843. Geneva, Switzerland: WHO; 1994.
6. Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consens Statement. 2000;17(1):1-45.
7. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Belle Mead, NJ: Excerpta Medica; 1999. Available at: www.nof.org/physguide. Accessed 7 November 2002.
8. US Congress, Office of Technology Assessment (OTA). Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy, Volume II: Evidence on Benefits, Risks, and Costs. OTA-BP-H-144. Washington, DC: Government Printing Office; 1995.
9. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res. 1994;9:1833-7.
10. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-45 [published erratum in JAMA 1999; 282:2124].
11. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609-17.
12. The North American Menopause Society. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause. 2002;9:84-101.
13. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33.
14. Tosteson A, Rosenthal DI, Melton LJ III, Weinstein MC. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med. 1990;113:594-603.
15. National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int. 1998;8(Suppl 4):S1-S88.
16. Zethraeus N, Johannesson M, Jonsson B. A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care. 1999;15:352-65.
17. Johnell O, Jonsson B, Jonsson L, Black D. Cost-effectiveness of alendronate (Fosomax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics. 2003;21:305-14.
18. Baron JA, Barrett J, Malenka D, et al. Racial differences in fracture risk. Epidemiology. 1994;5:42-7.
19. Barrett JA, Baron JA, Karagas MR, Beach ML. Fracture risk in the U.S. Medicare population. J Clin Epidemiol. 1999;52:243-9.
20. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ III. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992;7:221-7.
21. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118-24 [published erratum in J Clin Endocrinol Metab 2001;86:938].
22. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate: a meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA. 1997;277:1159-64.
23. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82.
24. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437-43.
25. Looker AC, Johnston CC Jr, Wahner HW, et al. Prevalence of low femoral bone density in older U.S. women from NHANES III. J Bone Miner Res. 1995;10:796-802.
26. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene oil risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA. 1999;281:2189-97 [published erratum in JAMA 1999;282:2124].
27. Browner WS, Pressman AR, Nevitt MC, Cummings SR. Mortality following fractures in older women: the study of osteoporotic fractures. Arch Intern Med. 1996;156:1521-5.
28. National Cancer Institute (NCI). 5-Year Relative Survival Rates for Selected Cancer Sites. All Races. Available from the National Institutes of Health NCI at seer.cancer.gov/publications/raterisk/ rates28.html. Accessed 7 November 2002.
29. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet. 2002;360:1131-5.
30. American Heart Association (AHA). 2002 Heart and Stroke Statistical Update. Dallas, TX: AHA; 2001.
31. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86:452-63.
32. Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. Ann Int Med. 2002;137:875-83.
33. US Bureau of Labor Statistics. Table 1A. Consumer Price Index for All Urban Consumers, by Service Group; various years.
34. US Bureau of the Census. Statistical Abstract of the United States. Washington, DC: Government Printing Office; 1996.
35. Centers for Medicare & Medicaid Services. National Physician Fee Schedule Relative Value File; 2001. Available at www.cms.hhs .gov/providers/pufdownload/. Accessed 25 March 2003.
36. Centers for Medicare & Medicaid Services. Medicare Home Health Prospective Payment System; 1999. Available at www.cms .hhs.gov/providers/ pufdownload/. Accessed March 2002.
37. American Association of Retired Persons. Nursing homes. Available at research.aarp.org/health/fs10r_nursing.html. Accessed February 2001.
38. Lee AJ, Huber J, Stason WB. Poststroke rehabilitation in older Americans: the Medicare experience. Med Care. 1996;34:811-25.
39. de Lissovoy G, Yusen RD, Spiro TE, Krupski WC, Champion AH, Sorenson SV. Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. Arch Intern Med. 2000;160:3160-5.
40. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40(8 Suppl):IV-104-17.
41. 2000 St. Anthony's RBRVS. Salt Lake City, UT: Ingenix; 2000.
42. Drug Topics Red Book. Montvale, NJ: Thomson Medical Economics; 2001.
43. CEA Registry: Standardizing the Methods and Practices of Cost-Effectiveness Analysis. Available from the Harvard School of Public Health at www.hsph.harvard.edu/cearegistry/. Accessed 6 November 2002.
44. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146:473-81.
45. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Int Med. 2003;163:1637-41.
46. US Bureau of the Census. Statistical Abstract of the United States. Washington, DC: Government Printing Office; 1999.